Suppr超能文献

在创伤/骨科手术后进行长时间的低分子量肝素血栓预防之前,是否应该告知患者肝素诱导的血小板减少症的风险?

Should patients be informed about the risk of heparin-induced thrombocytopenia before prolonged low-molecular-weight heparin thromboprophylaxis post-trauma/orthopedic surgery?

作者信息

Lubenow Norbert, Hinz Peter, Ekkernkamp Axel, Greinacher Andreas

机构信息

Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt-Universität, Greifswald, Germany.

出版信息

Eur J Haematol. 2007 Sep;79(3):187-90. doi: 10.1111/j.1600-0609.2007.00891.x. Epub 2007 Jul 26.

Abstract

OBJECTIVES

Heparin-induced thrombocytopenia (HIT) is an immune-mediated prothrombotic adverse drug effect that occurs less frequently with low-molecular-weight heparin (LMWH) than with unfractionated heparin (UFH) in post-trauma/orthopedic surgery patients. The life-threatening nature of HIT raises the question whether informed consent for this treatment-induced adverse effect should be obtained, particularly as LMWH is often continued during the outpatient period when clinical and platelet count monitoring become problematic. Paradoxically, refusal of thromboprophylaxis as a result of seeking informed consent could increase risk for thrombosis.

METHODS

We evaluated in patients undergoing routine LMWH thromboprophylaxis post-trauma/orthopedic surgery the feasibility of obtaining informed consent, using a standardized questionnaire to determine patient preferences. We also identified the proportion of HIT patients in our laboratory comprised of trauma/orthopedic surgery patients from 1995-1997 and 2002-2004 (time periods characterized, respectively, by UFH and LMWH thromboprophylaxis for this patient population).

RESULTS

None of 460 patients in whom informed consent was administered rejected LMWH thromboprophylaxis. The patients' perception of the informed consent process and the written information provided about the risk of HIT and its risk due to clinical consequences were highly favorable. From 1995-1997 to 2002-2004, the proportion of HIT identified among trauma/orthopedic surgery patients declined from 30.3% to 1.2% (P < 0.0001).

CONCLUSIONS

Obtaining informed consent about HIT is feasible in written form and does not cause refusal of LMWH thromboprophylaxis. Despite the uncommon occurrence of HIT during LMWH thromboprophylaxis, informed consent increases patient's awareness of this potentially life-threatening adverse drug effect, an outcome that could increase outpatient recognition of the diagnosis.

摘要

目的

肝素诱导的血小板减少症(HIT)是一种免疫介导的促血栓形成的药物不良反应,在创伤后/骨科手术患者中,低分子量肝素(LMWH)引起该不良反应的频率低于普通肝素(UFH)。HIT的致命性引发了一个问题,即对于这种治疗引起的不良反应是否应获得知情同意,特别是在门诊期间,当临床和血小板计数监测存在问题时LMWH仍经常继续使用。矛盾的是,因寻求知情同意而拒绝血栓预防可能会增加血栓形成的风险。

方法

我们在创伤后/骨科手术接受常规LMWH血栓预防的患者中,评估获得知情同意的可行性,使用标准化问卷来确定患者的偏好。我们还确定了1995 - 1997年和2002 - 2004年(分别以UFH和LMWH对该患者群体进行血栓预防为特征的时间段)在我们实验室中由创伤/骨科手术患者组成的HIT患者比例。

结果

在接受知情同意的460名患者中,没有一人拒绝LMWH血栓预防。患者对知情同意过程以及提供的关于HIT风险及其临床后果风险的书面信息评价很高。从1995 - 1997年到2002 - 2004年,在创伤/骨科手术患者中确定的HIT比例从30.3%降至1.2%(P < 0.0001)。

结论

以书面形式获得关于HIT的知情同意是可行的,且不会导致拒绝LMWH血栓预防。尽管在LMWH血栓预防期间HIT发生率不高,但知情同意提高了患者对这种潜在致命性药物不良反应的认识,这一结果可能会增加门诊对该诊断的识别。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验